Boehringer Ingelheim to collaborate with Molecular Partners
Boehringer Ingelheim has entered into a manufacturing agreement with Molecular Partners
Boehringer Ingelheim has announced a strategic collaboration agreement with Molecular Partners, a privately owned biotech company based in Switzerland.
Under the terms of the agreement, Boehringer Ingelheim will generate E coli production strains and manufacture tox and clinical stage material to support Molecular Partners' proprietary DARPin pipeline.
DARPins are a novel class of biologic drugs that are being developed by Molecular Partners for use in the fields of inflammation, oncology and ophthalmology, among others.
Simon Sturge, corporate senior vice-president of Boehringer Ingelheim Biopharmaceuticals, said: "We are happy to have entered into this collaboration with Molecular Partners as we believe the DARPin platform will play an important role in the development of next generation antibody-like proteins."
He added that the agreement reflects Boehringer Ingelheim's commitment to the development of highly innovative molecule platforms.
Dr Christian Zahnd, chief executive officer of Molecular Partners, described Boehringer Ingelheim as "the ideal partner", adding that the company intends to develop DARPin-based products "at highest quality and speed"
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta... -
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
.png)
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.